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ABSTRACT 
Trypanosoma brucei causes African sleeping 
sickness, for which no vaccine exists and available 
treatments are of limited use due to their high 
toxicity or lack of efficacy. T. brucei cultivated in 
the presence of deoxyadenosine accumulates high 
levels of dATP in an adenosine kinase-dependent 
process and dies within a few hours. Here we 
show that T. brucei treated with 1 mM 
deoxyadenosine accumulates higher dATP levels 
than mammalian cells but that this effect 
diminishes quickly as the concentration of the 
deoxynucleoside decreases. Radioactive tracer 
studies showed that the parasites are partially 
protected against lower concentrations of 
deoxyadenosine by the ability to cleave it and use 
the adenine for ATP synthesis. T. brucei 
methylthioadenosine phosphorylase (TbMTAP) 
was found to be responsible for the cleavage as 
indicated by the phosphate dependence of 
deoxyadenosine cleavage in T. brucei cell extracts 
and increased deoxyadenosine sensitivity in 
TbMTAP-knockdown cells. Recombinant 
TbMTAP exhibited higher turnover number (kcat) 
and Km values for deoxyadenosine than for the 
regular substrate, methylthioadenosine. One of the 
reaction products, adenine, inhibited the enzyme, 
which might explain why TbMTAP-mediated 
protection is less efficient at higher 
deoxyadenosine concentrations. Consequently, T. 
brucei grown in the presence of adenine 
demonstrated increased sensitivity to 
deoxyadenosine. In order for 
deoxyadenosine/adenosine analogues to remain 
intact and be active against the parasite, they need 
to either be resistant to TbMTAP-mediated 
cleavage, which is the case with the three known 
antitrypanosomal agents adenine arabinoside, 
tubercidin, and cordycepin, or they need to be 
combined with TbMTAP inhibitors.  
________________________________________ 
African sleeping sickness (1) is a fatal disease that 
progresses through two stages and is caused by 
two subspecies of the parasite Trypanosoma 
brucei – T. b. gambiense in Western and Central 
Africa and T. b. rhodesiense in Eastern and parts 
of Southern Africa. Treatment of the disease is 
particularly difficult in the second stage, in which 
the parasites leave the blood and lymph, enter the 
central nervous system, and eventually cause the 
patient to fall into a comatose state. T. brucei and 
related species also cause Nagana, a disease in 
cattle that has a significant impact on 
socioeconomic development in many parts of rural 
Africa (2).   
 http://www.jbc.org/cgi/doi/10.1074/jbc.M116.715615The latest version is at 
JBC Papers in Press. Published on April 1, 2016 as Manuscript M116.715615
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Many nucleoside analogues have been 
successfully used as drugs in the fields of cancer, 
virology, and to some extent parasitology. One 
advantage of using nucleoside analogues against 
second-stage sleeping sickness is that a large 
proportion of them can cross the blood-brain 
barrier via transporters used for the uptake of 
nucleosides needed by the brain (3). Nucleoside 
analogues need to be phosphorylated inside the 
cells into their nucleotide forms in order to inhibit 
transcription, replication, or other nucleotide-
dependent processes. In contrast to mammalian 
cells, which have several kinases to phosphorylate 
nucleosides and deoxynucleosides, T. brucei has 
only two – thymidine kinase primarily 
phosphorylates thymidine and deoxyuridine (4,5), 
and adenosine kinase phosphorylates adenosine 
and, to some extent, deoxyadenosine (6).  
T. brucei lacks de novo purine biosynthesis, and 
adenosine kinase is part of the efficient salvage 
pathways that enable the parasite to utilize 
nucleosides and bases from the host (7). 
Adenosine is one of the major purine sources in 
human blood where the concentration is 2 μM (8). 
It is taken up by T. brucei via efficient transporters 
(9,10) and phosphorylated by adenosine kinase 
into AMP and subsequently by other kinases into 
ADP and ATP (7). An alternative pathway that 
adenosine shares with other purine nucleosides is 
that the ribose moiety can be first cleaved off and 
the base salvaged instead. The adenosine cleavage 
reaction is catalyzed by inosine-adenosine-
guanosine-nucleoside hydrolase (IAG-NH) (11). 
Although the relative contribution of each pathway 
for adenosine salvage is not known, the much 
higher affinity of adenosine kinase than IAG-NH 
for this substrate suggests that it represents the 
major route (6). As a side activity, T. brucei 
adenosine kinase is also able to phosphorylate 
deoxyadenosine (6). This reaction is detrimental to 
the parasites because addition of 0.5 mM 
deoxyadenosine to the culture medium causes the 
parasites to die within 15 hours with grossly 
elevated dATP levels and a concomitant decrease 
in ATP, which is consumed in the phosphorylation 
of the deoxynucleoside (12).  
Many adenosine analogues are metabolized in a 
similar manner as adenosine into their nucleotide 
forms and affect transcription and other ATP-
dependent processes. Cordycepin (3´-
deoxyadenosine) and tubercidin (7-
deazaadenosine) are two such analogues that 
inhibit T. brucei growth with IC50 values in the 
nanomolar range (13). Cordycepin has been shown 
to cure both stages of the disease in T. brucei-
infected mice when given together with 
deoxycoformycin, which protects the drug from 
deamination by serum adenosine deaminase (14). 
Promising results have also been obtained with 2-
fluorocordycepin, which is resistant to adenosine 
deaminase and can be used as a single agent (15). 
So far, the development of antiparasitic nucleoside 
derivatives has focused mainly on ribonucleoside 
analogues such as cordycepin and tubercidin, 
whereas 2´-deoxynucleoside and arabinoside 
analogues are the ones most frequently used in 
anticancer and antiviral therapies. Arabinoside 
analogues can be considered equivalent to 
deoxynucleoside analogs because they are 
generally phosphorylated by the same kinases as 
deoxynucleosides and primarily inhibit DNA 
synthesis and other deoxynucleotide-dependent 
reactions. Adenine arabinoside (Ara-A) is an 
example of one such analogue that in combination 
with deoxycoformycin inhibits T. brucei DNA 
synthesis and cures T. brucei-infected mice (6).  
The sensitivity of T. brucei to deoxyadenosine 
seems surprising in light of the fact that this is a 
naturally occurring nucleoside. In the current 
work, we show that T. brucei methylthioadenosine 
phosphorylase (TbMTAP) normally protects T. 
brucei cells against deoxyadenosine, but product 
inhibition by adenine sets an upper level on the 
capacity of the enzyme. Knowledge of the 
TbMTAP-mediated protection system is relevant 
for drug discovery because adenosine kinase 
substrate analogues need to be resistant to 
cleavage by TbMTAP (and TbIAG-NH) or be 
combined with cleavage enzyme inhibitors in 
order to be active against the parasite. 
Consequently, we found that cordycepin, 
tubercidin, and Ara-A were all resistant to 
TbMTAP activity and that the presence of the 
TbMTAP inhibitor adenine in the culture medium 
could increase deoxyadenosine-induced growth 
inhibition of T. brucei bloodstream forms (BSFs).  
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Experimental Procedures. 
Cultivation of T. brucei and mammalian cells. 
T. brucei BSFs were cultivated at 37C in HMI-9 
medium (16) supplemented with 10% (v/v) heat-
inactivated fetal bovine serum (Gibco, Carlsbad, 
CA, USA) and grown in a humidified atmosphere 
containing 5% CO2. T. brucei procyclic forms 
were cultivated with similar atmospheric 
conditions at 27C in SDM-79 medium (Gibco) 
containing 10% (v/v) heat-inactivated fetal bovine 
serum and 1 µg/ml hemin (Sigma-Aldrich, St. 
Louis, MO, USA) (17). Madin Darby Bovine 
Kidney cells (MDBK cells, ATCC no. CCL-22) 
and mouse Balb/3T3 fibroblasts (ATCC no. CCL-
163) were cultivated as monolayers in Dulbecco’s 
modified Eagle’s medium (Sigma-Aldrich) 
supplemented with L-glutamine (0.584 g/l), 10% 
(v/v) heat-inactivated fetal bovine serum, and 10 
ml/l 100× penicillin-streptomycin (Gibco) at 37C 
in a humidified atmosphere containing 7% CO2. 
Suspensions of human promyelocytic leukaemia 
cells (HL-60 cells, ATCC no. CCL-240) were 
cultivated in RPMI-1640 (Gibco) supplemented 
with 10% (v/v) heat-inactivated fetal bovine 
serum. Growth conditions and additional 
supplements (glutamine, penicillin, and 
streptomycin) were the same as for the Balb/3T3 
and MDBK cells. 
Nucleotide pool measurements. NTP and dNTP 
pools from T. brucei and mammalian cells were 
extracted as described previously (12) and 
quantified by PolyWAX A (PolyLC, Columbia, 
MD, USA) chromatography (18). A change 
compared to the previous analyses (12) is that here 
we used the regular T. brucei HMI-9 medium and 
did not exclude thymidine. The connection of the 
HPLC equipment to a flow scintillation analyzer 
(Radiomatic 150TR, Perkin Elmer, Waltham, MA, 
USA) enabled the detection of radiolabeled 
metabolites in experiments where the cells were 
treated with [2,8-3H]-labeled deoxyadenosine 
(Moravek Biochemicals, Brea, CA, USA).  
Preparation of T. brucei cell extracts. T. brucei 
TC221 cells were grown to a cell density of 2 × 
106 cells/ml (50–100 ml) and centrifuged at 3,000 
× g for 10 min at 4°C. The pellet was washed with 
phosphate-buffered saline (PBS), recentrifuged, 
and resuspended in 200 µl of 10 mM Tris-HCl pH 
7.6. The resulting suspension was vortexed with 
zirconium beads to lyse the cells and 
recentrifuged. The supernatant was flash frozen in 
liquid nitrogen and stored at −80°C. The protein 
concentration was determined by the Bio-Rad 
protein assay using bovine serum albumin as the 
reference. Enzyme assays were performed in the 
same manner as with the recombinant TbMTAP 
(see below) except that the phosphate 
concentration was decreased to 5 mM because 
cleavage of adenosine was inhibited at higher 
concentrations in the cell extracts (most likely due 
to inhibition of IAG-NH).  
Measurement of IC50 values in T. brucei. T. 
brucei cells were seeded in 96-well microtiter 
plates (5,000 cells/well for BSFs and 20,000 
cells/well for procyclics) containing 200 µl culture 
medium with various concentrations of 
deoxyadenosine or nucleoside analogues (in 
combination with 2 µM deoxycoformycin). After 
48 hours, the plates were incubated for 24 hours 
with 20 µl of Alamar Blue dye (Invitrogen, 
Carlsbad, CA, USA) and quantified by 
fluorescence (540 nm excitation and 590 nm 
emission) using an Infinite M200 microplate 
reader (Tecan Group, Männedorf, Switzerland). 
The low number of cells (5,000 cells/well) for 
testing deoxyadenosine sensitivity of BSFs was an 
adjustment because adenine (formed from the 
cleavage of deoxyadenosine) became detectable in 
the growth medium at significant levels if the 
number of cells were higher. The IC50 values were 
determined by fitting the data to a log [inhibitor] 
vs. response curve (variable slope, four 
parameters) using the GraphPad Prism 5.04 
software (GraphPad Software, La Jolla, CA, 
USA).   
TbMTAP RNA interference. Approximately 400 
bp of the TbMTAP gene was amplified from T. 
brucei TC221 genomic DNA by using the primers 
5’-GTC ACC TCG AGT GCC AAC TTC CGG 
AAG C -3’ (forward primer, the XhoI site is 
underlined) and 5’-AGC ACA AGC TTC TTT 
GTA ATG GCC TCT GGT TT -3’ (reverse 
primer, the HindIII site is underlined). The PCR 
product was digested with XhoI and HindIII 
restriction enzymes and ligated into pZJM (19). 
The resulting pZJM-TbMTAP construct was 
linearized with NotI and transfected into NY-
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single-marker T7NAP/TetR T. brucei BSFs (20) 
by electroporation (19), and positive clones were 
selected in the presence of 0.5 µg/ml phleomycin 
and 1 µg/ml G418 (20). Expression of the 
TbMTAP RNAi construct was induced with 1 
µg/ml of tetracycline for 7 days.  
Western blot analysis. Zirconium bead-
homogenized T. brucei cell extracts (see above) 
were analyzed by Western blot using an anti-
TbMTAP immune serum, which was produced by 
Agrisera AB (Vännäs, Sweden) using 
recombinantly expressed and purified TbMTAP 
(see below) as the antigen. The Western blot was 
carried out using the antibody diluted 10,000-fold 
in Tris-buffered saline/Tween 20 (TBST) 
containing 2% (w/v) skim milk. After incubation 
over night, the membrane was washed and probed 
with an anti-rabbit secondary antibody for 1 h (GE 
Healthcare, Chalfont St. Giles, UK), developed 
with the ECL system (GE Healthcare), and imaged 
with the ChemiDocTM Touch Imaging System 
(Bio-Rad, Hercules, CA, USA). For the 
determination of the loading control, the 
membrane was washed and incubated for 2 h with 
anti-BiP antibody used at 10,000-fold dilution (the 
antibody recognizes Binding protein (BiP), a 
member of the hsp70 heat shock protein family). 
The membrane was probed with secondary 
antibody and analyzed by ECL detection as 
described above. The anti-BiP antibody was a kind 
gift from J. Bang’s laboratory at the University of 
Wisconsin Medical School.  
Expression and purification of recombinant 
TbMTAP. The TbMTAP gene was amplified from 
T. brucei TC221 genomic DNA by using the 
primers 5’ - AAC TGC TCA TGA TGT ACA 
CGA GTC CCC ACG - 3’ (TbMTAP forward 
primer, the BspHI site is underlined) and 5’ - ACG 
GGG TAC CTA TTA CGG AGC GAA TAT 
GGG ATA TTT - 3’ (TbMTAP reverse primer, the 
Acc65I site is underlined). The PCR product was 
digested with BspHI and Acc65I and subcloned 
into a pETM-20 vector (European Molecular 
Biology Laboratory) that had been digested with 
NcoI (an isoschizomer of BspHI) and Acc65I. 
DNA sequencing from both directions confirmed 
the inserted gene to be correct. The resulting 
plasmid (pETM-20-TbMTAP) encodes a fusion 
construct with TbMTAP connected to an N-
terminal His-tagged TrxA protein via a linker 
containing a TEV protease recognition site. The 
vector pETM20-TbMTAP was transformed into 
Escherichia coli BL21 (DE3) pLysS cells 
(Merck), grown at 37C in 1 l Luria-Bertani broth 
supplemented with 60 μg/ml carbenicillin and 27.2 
μg/ml chloramphenicol, induced at OD595 = 0.5 
with 1 mM isopropyl-β-D-thiogalactopyranoside 
(IPTG), and harvested 3 h later. The bacteria were 
centrifuged and the pellet resuspended in 25 ml 
buffer A (0.3 M NaCl and 20 mM Tris-HCl, pH 
7.8). After freezing and thawing and 
ultracentrifugation at 150,000 × g for 45 min, the 
supernatant was loaded onto a 1-ml nickel-NTA 
Superflow column (Qiagen, Hilden, Germany) 
equilibrated with buffer A. The column was 
subsequently washed with 15 ml of 5 mM and 
then 10 ml of 10 mM imidazole in buffer A. TrxA-
tagged TbMTAP protein was finally eluted with 
25 ml of 100 mM imidazole in buffer A. The 
eluted fractions were pooled and concentrated by 
two different methods. When adenine-free protein 
was required, the solution was precipitated with 
ammonium sulfate at 80% saturation at 4C 
(nominally 0.53 g/ml), centrifuged, and the pellet 
dissolved in 600 µl buffer B (50 mM Tris-HCl pH 
7.6 and 0.1 mM DTT). When yield and stability 
was of higher importance (general protocol), the 
protein was concentrated in a 20 ml Vivaspin 
concentrator with a 30 kDa molecular mass cutoff 
(Sartorius AG, Goettingen, Germany) to a final 
volume of 600 µl. The concentrated protein (using 
either of the two concentration methods) was 
buffer-exchanged into buffer B with a PD-10 
Sephadex G-25 gel filtration column (GE 
Healthcare). TrxA-TbMTAP protein in 7.5 ml of 
buffer B was mixed with TEV protease (2:1 ratio 
in milligrams) and incubated overnight at 4C. The 
digested protein mix was loaded onto a 1 ml 
nickel-NTA Superflow column (Qiagen) 
equilibrated with buffer B, and TbMTAP-
containing fractions collected in the flow-through 
were subsequently pooled, concentrated by using a 
30 kDa cutoff 20 ml Vivaspin concentrator 
(Sartorius AG), frozen in liquid nitrogen, and 
stored at −80C. The Bio-Rad protein assay was 
used to assess the protein concentration with 
bovine serum albumin as the reference. The 
typical yield was 13 mg TbMTAP from 1 l of 
bacterial culture using the general protocol. In 
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enzyme assays using MTA, adenosine, or 
deoxyadenosine as substrates, the effect of adenine 
from the TbMTAP stock was negligible because 
strongly diluted protein solutions were used. With 
guanosine, inosine, and other low-affinity purines 
and pyrimidines, much more enzyme was needed, 
and it was then crucial to use protein purified with 
the extra ammonium sulfate precipitation step. 
TbMTAP Assays. A buffer consisting of 50 mM 
potassium acetate, 50 mM Tris-HCl pH 7.4, and 
0.05% (v/v) Tween-20 was used to dilute the 
enzyme to an appropriate concentration (0.05–
1000 ng/µl depending on the substrate) prior to 
use in enzyme assays. The diluted enzyme 
(generally 2 µl) was mixed with a solution 
containing the nucleoside substrate in a total 
volume of 100 µl of 50 mM KH2PO4 pH 7.4 (pH-
adjusted with KOH). In assays where the reverse 
reaction was studied (nucleoside synthesis), the 
phosphate buffer was replaced by 50 mM HEPES-
KOH pH 7.4. The enzyme assay was incubated for 
30 min at 37°C. The reaction was terminated by 
incubation at 100°C for 2 min in a heating block, 
and the reaction product was quantified by HPLC 
using an ACE UltraCore 2.5 Super C18 50 × 2.1 
mm column (Advanced Chromatography 
Technologies, Aberdeen, UK). The column was 
run isocratically at 0.4 ml/min using a mobile 
phase consisting of 30 mM ammonium acetate pH 
5.8 and 5% (v/v) methanol. This procedure was 
sufficient to separate adenine (natural or modified) 
from each nucleoside substrate. Assays with 
guanine, hypoxanthine, cytosine, uracil, or 
thymine as reaction products were analyzed at 1 
ml/min on an ACE 3 AQ 50 × 4.6 mm column 
(Advanced Chromatography Technologies) to 
enable the use of a methanol-free mobile phase (40 
mM ammonium acetate pH 5.8). All enzyme 
assays were performed within the linear range 
with respect to time and protein concentration.  
Results 
dATP accumulates in deoxyadenosine-treated 
T. brucei BSFs and mammalian cells. Generally, 
the levels of dNTPs are much lower than NTPs in 
T. brucei cells (12). However, when cultivated in 
the presence of 1 mM deoxyadenosine in the 
growth medium for 1 h, dATP became the most 
abundant nucleotide in the cell (Fig. 1A). 
Similarly to what was observed previously (12), 
the level of ATP, which is needed for the 
phosphorylation of deoxyadenosine, decreased 
significantly under these conditions (p < 0.001, 
unpaired t-test). The level of dCTP increased and 
dGTP decreased (Fig. 1A, inset) as a result of the 
effect of dATP as a specificity regulator of 
ribonucleotide reductase (12). Unlike in 
mammalian cells (21), dATP does not act as an 
overall activity inhibitor of the T. brucei 
ribonucleotide reductase (12,22), and there was, 
therefore, no general decrease of the dNTP levels 
in Fig. 1. The dTTP levels were much higher here 
than reported previously (12) due to the fact that 
we used regular HMI-9 growth medium, which 
contains 1 mM thymidine (16). The effect of 
deoxyadenosine on dNTP pools is likely to cause 
inhibition of DNA synthesis and an increased 
number of replication errors (23), whereas ATP 
depletion might cause more acute cytotoxicity.  
In Fig.1B, the dATP accumulation in T. brucei is 
shown as a function of the deoxyadenosine 
concentration in the growth medium. The data are 
plotted in two different ways. Presenting the data 
as a percentage of the total nucleotide pool (NTPs 
+ dNTPs) has many advantages, including smaller 
standard errors, less variation depending on who is 
performing the experiment, and the possibility of 
comparing cell types with different volumes and 
thereby different total nucleotide levels. Because 
the increased dATP pool is to a large extent 
compensated for by a decrease in the other 
nucleotides, the two curves in Fig. 1B have fairly 
similar shapes. It is only when dATP becomes the 
major nucleotide in the cell (the 1 mM data point) 
that the total nucleotide pool increases 
significantly and creates a slight deviation between 
the two curve shapes.            
The deoxyadenosine salvage efficiency of T. 
brucei was compared to mammalian cells selected 
from different species and cell types in order to 
make the results more generalizable. The data 
were shown as percentages of the total nucleotide 
pool to be able to compare the different cell types. 
T. brucei incubated with 1 mM deoxyadenosine 
accumulated a much higher percentage of dATP 
than the three mammalian cell types that were 
tested (Fig. 1C). This difference between T. brucei 
and mammalian cells is in fact slightly larger than 
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in Fig. 1C if the deviation of the total nucleotide 
pool described in Fig. 1B is taken into account in 
the normalization procedure. The efficient 
deoxyadenosine salvage is consistent with the 
extraordinarily high affinity of all T. brucei 
adenosine transporters for deoxyadenosine 
(9,24,25). Despite the unusually efficient 
transport, the cellular percentage of dATP in T. 
brucei decreased very sharply at lower 
concentrations of deoxyadenosine and was then in 
the same range as in the mammalian cells, which 
all showed a more gradual relationship between 
the deoxyadenosine concentration and dATP 
accumulation. The comparatively low level of 
deoxyadenosine salvage at ≤ 0.25 mM in T. brucei 
suggested that the parasite has a protective system 
against deoxyadenosine, although this activity 
seems limited by an additional factor that prevents 
it from working efficiently at higher 
concentrations of the deoxynucleoside.  
Deoxyadenosine is cleaved by T. brucei cells. To 
investigate possible protection mechanisms against 
deoxyadenosine, T. brucei BSFs were incubated 
with different concentrations of [2,8-3H]-
deoxyadenosine, and the distribution of 
radioactive label in their ATP and dATP pools was 
analyzed (Table 1). There was no label detected in 
GTP, dGTP, or pyrimidine nucleotides. At the 
lower 3H-deoxyadenosine concentrations tested, 
most of the label appeared in the ATP pool, and 
this suggested that the nucleoside was cleaved and 
the labeled adenine salvaged into ATP, 
presumably by adenine phosphoribosyltransferase 
(APRT) (7,26). A gradual decrease in radioactivity 
in the ATP pool at higher concentrations of 3H-
deoxyadenosine in Table 1 indicated that the 
cleavage activity could be saturated and that the 
label went into dATP instead.  
It should also be noted that a minor fraction of the 
radioactivity in dATP can come from ADP that is 
used as a substrate for ribonucleotide reductase. 
However, this cross-talk is inhibited by dATP, 
which acts as a specificity regulator of 
ribonucleotide reductase in T. brucei (12), and this 
is primarily relevant for the first data point. 
Deoxyadenosine cleavage in T. brucei cell 
extracts is phosphate dependent. The two known 
adenosine/deoxyadenosine cleavage activities in T. 
brucei – TbMTAP and TbIAG-NH – are 
phosphate-dependent and phosphate-independent, 
respectively (11,27). Analysis of deoxyadenosine 
cleavage in T. brucei cell extracts showed that the 
reaction was dependent on phosphate ions, 
suggesting cleavage by TbMTAP (Fig. 2A), 
whereas the corresponding reaction with 
adenosine was phosphate-independent, suggesting 
cleavage by TbIAG-NH (Fig. 2B). It is also clear 
that the total adenosine cleavage activity is much 
higher than with deoxyadenosine. If there is any 
TbMTAP-mediated adenosine cleavage, it is 
therefore likely to be overshadowed by that of 
TbIAG-NH.  
TbMTAP is able to protect T. brucei from 
deoxyadenosine. To investigate whether or not 
TbMTAP is able to protect T. brucei from 
deoxyadenosine, we created a tetracycline-
inducible TbMTAP RNA interference construct 
and selected for its expression in NY-single-
marker T7NAP/TetR (NYSM) T. brucei BSFs. 
Tetracycline induction of the knockdown construct 
for seven days resulted in greatly reduced 
TbMTAP levels (Fig. 3A). Comparing the wild-
type T. brucei lane (TC221 cells) in the 
immunoblot with the left lanes containing different 
amounts of recombinant protein showed that the 
cellular sample contained approximately 3 ng 
TbMTAP and, consequently, that the cellular level 
of this protein was ~0.1% of the total protein (3.6 
µg). A similar comparison of the other cellular 
extract lanes in Fig. 1A with the recombinant 
protein shows that the level of TbMTAP decreases 
at least 2-fold in the non-induced cells and ~16-
fold in the induced cells as compared to the 
NYSM cells. The small reduction of TbMTAP 
levels observed in the non-induced cells could be 
due to some RNAi expression leakage in the 
absence of tetracycline. The expression leakage in 
the non-induced cells had a tendency to increase 
over time making it important to minimize the 
number of cellular generations. A second probing 
carried out with anti-BiP antibody confirmed that 
the loading was fairly equal in the four cellular 
extract lanes in Fig. 3A (the recombinant protein 
in the left lanes does not contain this protein). The 
protective role of TbMTAP against 
deoxyadenosine was demonstrated by IC50 value 
measurements, which showed a gradually 
increased sensitivity to deoxyadenosine between 
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NYSM, non-induced, and induced cells (Fig. 3B). 
Note that the decrease in TbMTAP levels in the 
non-induced cells as compared to NYSM led to a 
proportional increase in deoxyadenosine 
sensitivity but that the effect of further reduction 
of TbMTAP levels was quickly saturated. 
Consequently, the induced cells with much lower 
TbMTAP levels only had a two-fold increased 
deoxyadenosine sensitivity as compared to the 
non-induced cells.   
Recombinant TbMTAP expression and 
purification. TbMTAP was expressed in E. coli as 
a fusion construct with an N-terminal His-tagged 
thioredoxin A (TrxA) partner, which enabled the 
purification by nickel-NTA agarose 
chromatography. SDS-PAGE analysis of the 
protein after removal of the fusion partner showed 
that it was pure and migrated according to its 
theoretical molecular mass of 34 kDa (Fig. 4A).  
TbMTAP is inhibited by adenine. Optimization 
of the enzyme assay conditions for TbMTAP 
showed that the protein had a broad pH optimum 
and was not dependent on common supplements 
such as Na+, K+, Mg2+, or DTT (Fig. 4B-C). Most 
supplements had no obvious effect on enzyme 
activity except Tris-HCl and high concentrations 
of chloride salts (200 mM), which were slightly 
inhibitory. Similarly to other nucleoside 
phosphorylases, it could catalyze the enzymatic 
reaction in both directions, although the cleavage 
reaction (phosphorylysis) was more efficient than 
the synthesis reaction (Fig. 4D). By studying the 
enzyme activity in the presence of 50 mM 
phosphate (Pi), a concentration nearly 100 times 
above the Km value for Pi (Table 2), the synthesis 
reaction became undetectable and we could 
selectively study the cleavage reaction. The linear 
range of the TbMTAP cleavage activity with 
respect to protein concentration was very limited 
(Fig. 4D), and it needed to be carefully optimized 
for each substrate. Deviation from linearity starts 
to be apparent already at 2 pmol/min in the figure, 
which corresponds to 0.6% substrate conversion 
during the 30-min incubation time. The limited 
linear range can be explained by the observation 
that the enzyme activity was strongly inhibited by 
adenine, a product in the reaction, which acted as a 
competitive inhibitor (Fig. 4E). The Ki value was 
calculated to be 0.56 ± 0.07 µM from the 
corresponding Michaelis-Menten graphs by non-
linear regression using the GraphPad Prism 
software. 2-fluoro-2´-deoxyadenosine was used as 
the substrate in the inhibition studies in order to be 
able to get a product (2-fluoroadenine) that can be 
separated from the inhibitor (adenine). The 
catalytic parameters are fairly similar with this 
substrate as with deoxyadenosine (Table 2).  
TbMTAP substrate analysis. TbMTAP was 
highly selective for adenine-containing 
nucleosides as compared to other natural purines 
and pyrimidines (Table 2). It had good activity 
with methylthioadenosine (MTA), adenosine, and 
deoxyadenosine, although with very different 
kinetic parameters for the three substrates. The 
much lower Km value (and higher catalytic 
efficiency) for MTA indicates that this is a first 
priority substrate. In contrast, deoxyadenosine and 
adenosine are high Km substrates with high 
turnover numbers (kcat), indicating that the enzyme 
is only able to cleave the nucleosides efficiently 
when they are present at high concentrations 
relative to MTA. Cleavage reactions with 
adenosine as the substrate were kinetically similar 
to those with deoxyadenosine (less than a two-fold 
difference in kcat, Km, and catalytic efficiency). 
Interestingly, the Km values for deoxyadenosine 
and adenosine were an order of magnitude higher 
than the Ki value of adenine indicating the strength 
of this inhibitor.  
TbMTAP and adenosine analogues. Enzyme 
assays with some known antitrypanosomal 
adenosine analogues showed that tubercidin, Ara-
A, and cordycepin were all poor substrates (Table 
2). There was no measurable activity with 
tubercidin, and very low catalytic efficiency with 
Ara-A. The kcat value with cordycepin was in the 
same range as the main substrates of the enzyme, 
but the Km value was very high leading to a low 
catalytic efficiency for this substrate as well. A 
general trend seems, therefore, to be that known 
antitrypanosomal agents can circumvent 
TbMTAP-based cleavage, which would explain 
their efficiency. Halogenation of the 2-position of 
the base is a common way to make adenosine 
analogues resistant to deamination and thereby 
stable in the blood. We therefore tested the 2-
fluorinated and 2-chlorinated analogues of 
deoxyadenosine (Table 2). Both were good 
 at G
lasgow
 U
niversity Library on O
ctober 3, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
8	
	
substrates, and these modifications seemed to only 
have a modest effect on TbMTAP cleavage.  
Adenine promotes the antitrypanosomal 
activity of deoxyadenosine. T. brucei BSFs 
showed enhanced sensitivity to deoxyadenosine in 
the presence of non-toxic concentrations of 
adenine (Table 3), supporting our conclusion that 
TbMTAP is inhibited by adenine. The 
concentration of adenine used here was confirmed 
to not affect growth by itself prior to the 
experiment. Similar experiments with the 
adenosine analogues Ara-A and cordycepin 
showed that the sensitivities to these compounds 
were not enhanced in the presence of adenine. 
With Ara-A, there was no adenine effect at all, and 
with cordycepin the sensitivity was slightly 
decreased instead of increased. The IC50 value 
with Ara-A was approximately three-fold higher 
than reported previously (6), and this deviation 
might be explained by the fact that here we used 
regular HMI-9 medium (with thymidine) and a 
different incubation time. Our conclusion about 
the role of adenine in TbMTAP inhibition was also 
confirmed in knockout T. brucei procyclic cells, 
which lack the two genes for APRT (26). Lacking 
APRT makes these cells unable to use the adenine 
from deoxyadenosine cleavage for AMP 
biosynthesis, leading to adenine inhibition of 
TbMTAP and increased deoxyadenosine 
sensitivity (Table 3).  
Discussion 
The most well-known protection mechanism 
against deoxyadenosine is via adenosine 
deaminase. Deficiency of this enzyme in humans 
leads to high dATP levels in lymphocytes, which 
results in lymphocytopenia and, consequently, 
severe combined immunodeficiency (SCID) (28). 
It has been unclear, however, what level of 
protection T. brucei has against deoxyadenosine. 
Adenosine deaminase activity was initially 
reported from T. brucei cell extracts (29), but this 
finding could not be confirmed by other 
laboratories (30). The adenosine deaminase-like 
sequences reported from the genomes of T. brucei 
and related species in GenBank (e.g. 
EAN78471.1) are homologous to tRNA-editing 
enzymes and are thus not likely to work on the 
nucleoside level. Here, we have found that 
TbMTAP instead has the role of protecting the 
parasites against deoxyadenosine by cleaving it 
into adenine and deoxyribose-1-phosphate. 
Characterization of the recombinant TbMTAP 
sheds light onto how its enzymatic function is 
optimized for a dual role in the cell (Fig. 5). First, 
it needs to cleave MTA efficiently in order to keep 
the methionine cycle and polyamine metabolism 
going. Thus the enzyme has a low Km (and a high 
catalytic efficiency) for MTA as a substrate 
compared to adenosine and deoxyadenosine. It is 
known from a previous study that knocking down 
TbMTAP leads to slightly slower growth and an 
increased proportion of anucleate and 
multinucleate T. brucei cells (31). The effect on 
the DNA content could possibly be a result of 
defective metabolism of polyamines, which are 
needed to stabilize DNA during replication.  
Second, TbMTAP needs to cleave deoxyadenosine 
to prevent any buildup of dATP. A comparatively 
high Km value for this substrate prevents it from 
competing for MTA cleavage. The 
deoxyadenosine concentrations used here are 
much higher than what can be expected to occur in 
the natural environment of the parasites, but it 
should be remembered that the HMI-9 growth 
medium contains hypoxanthine as the only purine 
source and there is no selective pressure for the 
parasites to keep the adenosine salvage systems 
upregulated. It is, for example, common that in 
vitro cultivated parasites lose almost all of their P2 
nucleoside transporter activity, which transports 
adenine, adenosine and deoxyadenosine (32); 
apparently the transporter is downregulated under 
standard culture conditions. Although this does not 
eliminate all deoxyadenosine uptake, which can 
also occur by the P1 nucleoside transporter (9), the 
fact that T. brucei transporters can be differentially 
expressed under different conditions (33) suggests 
that in vitro IC50 values may not necessarily reflect 
in vivo sensitivities. In the human host, the 
concentration of deoxyadenosine is usually below 
the detection limit in the blood due to the action of 
adenosine deaminase. Nevertheless, it is important 
for the parasite to also have a protection system of 
its own; in studies on T. evansi-infected rats it was 
found that the infection leads to downregulation of 
the adenosine deaminase in the blood and some 
parts of the brain (34,35). An even more 
unpredictable situation can be imagined to occur 
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for the trypanosomes in the midgut of the tsetse fly 
where the deoxyadenosine concentration will be a 
direct consequence of what the insect feeds on.     
A previous report using a partially purified 
preparation of TbMTAP found that the enzyme 
has a broader substrate specificity than the 
mammalian enzyme and can cleave MTA along 
with adenosine, deoxyadenosine, and cordycepin 
(27). However, the enzyme activity measurements 
alone indicate that these other substrates can never 
compete with MTA, for which the enzyme has a 
much lower Km value and higher catalytic 
efficiency. Here, we have studied both the isolated 
enzyme and deoxyadenosine metabolism in living 
T. brucei cells. Experiments with radiolabeled 
deoxyadenosine demonstrated that the reaction is 
efficient in T. brucei cells despite the much lower 
catalytic efficiency with this substrate as compared 
to MTA. When present at a concentration of 10 
μM in the growth medium, most of the 
deoxyadenosine taken up by the cells was cleaved 
and 97% of the label was incorporated into ATP 
instead of dATP. No label was detected in GTP, 
dGTP, or other NTPs or dNTPs. The presence of 
the 3H-label in ATP indicates that a major 
metabolic route for adenine is phosphoribosylation 
to AMP (and subsequent phosphorylation to ADP 
and ATP). If the adenine would be deaminated 
prior to salvage, the label would be expected to 
occur in both ATP and GTP, which was not the 
case. The deoxyadenosine protection mechanism 
was confirmed in TbMTAP knockdown T. brucei 
cells, which, upon induction of the RNAi 
construct, became five times more sensitive to 
deoxyadenosine. The deoxyadenosine cleavage 
reaction seems, therefore, to occur efficiently in 
the cell despite the much higher Km for this 
substrate as compared to MTA. A possible 
explanation could be that MTA is immediately 
metabolized as soon as it is produced and does not 
accumulate to levels high enough to outcompete 
deoxyadenosine cleavage. 
The TbMTAP-mediated protection system against 
deoxyadenosine in T. brucei seems to have an 
upper limit of how much deoxyadenosine it can 
process; the reaction is very efficient with 10 μM 
3H-deoxyadenosine in the growth medium but 
gradually loses capacity at higher concentration of 
the nucleoside leading to dATP pool expansion 
and an increased ratio of radiolabel in dATP as 
compared to ATP. As illustrated in Fig. 5, the 
cellular adenine concentration contributes to this 
limit of the protection system when the production 
of adenine exceeds the only metabolic use by 
APRT. T. brucei BSFs grown in the presence of 
adenine thus showed an enhanced sensitivity to 
deoxyadenosine, and characterization of the 
recombinant TbMTAP showed that adenine was a 
strong competitive inhibitor of deoxyadenosine 
cleavage (Ki = 0.56 µM). The low Ki value means 
that adenine easily outcompetes deoxyadenosine 
(Km = 8.3 µM) but has much less effect on enzyme 
activity with the high-affinity substrate MTA (Km 
= 0.09 µM). We believe that a major reason why 
the protection system fails at high concentrations 
of deoxyadenosine is because APRT does not 
metabolize the adenine efficiently enough. The 
role of APRT in this pathway was supported by 
our observation that knockout cells lacking this 
enzyme showed enhanced sensitivity to 
deoxyadenosine.  
The discovery of the deoxyadenosine protection 
system is very important for the rational 
development of adenosine and deoxyadenosine 
analogues against African sleeping sickness. Many 
of these analogues are only active against T. 
brucei in their nucleoside form, and then they need 
to be resistant to cleavage by both TbMTAP and 
TbIAG-NH. For 2´-deoxyadenosine analogues, 
TbMTAP is the more important of the two 
enzymes to consider (Fig. 5). As shown in Table 2, 
most nucleosides are to varying degrees substrates 
of the TbMTAP reaction, but a majority of them 
gave very low activity, including nearly all natural 
nucleosides except the ones containing adenine. 
Interestingly, the known antitrypanosomal 
nucleoside analogues tested were all very poor 
substrates in the reaction; tubercidin gave no 
detectable enzyme activity and the catalytic 
efficiencies with cordycepin and Ara-A were 100 
and 105 times lower, respectively, than with 
deoxyadenosine showing that the N7 and 3’-OH 
moieties must be important for substrate binding 
and/or catalysis, whereas the effect of the 2’-OH 
group is strongly dependent on its orientation.  
Similar conclusions were drawn from our 
experiments on cultivated trypanosomes, which 
became more sensitive to deoxyadenosine but not 
to cordycepin and Ara-A when incubated in the 
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presence of the TbMTAP inhibitor adenine. A 
prerequisite for these nucleoside analogues to be 
efficient as antitrypanosomal agents is that they 
remain intact and are not cleaved. Nucleoside 
analogues that are TbMTAP substrates need to be 
combined with TbMTAP inhibitors such as 
adenine or, preferably, a stable adenine analogue 
that is not an APRT substrate but an equally 
effective TbMTAP inhibitor. A possible 
alternative might be to create prodrug analogues 
that only become cytotoxic after cleavage and that 
need the selective activation by TbMTAP to target 
the parasites.  
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Figure Legends 
Fig. 1. Deoxyadenosine salvage in T. brucei TC221 and mammalian cells. (A) Nucleotide pools in T. 
brucei bloodstream forms cultivated in the absence (black bars) or presence of 1 mM deoxyadenosine 
(white bars). The inset shows a magnification of the dCTP, dTTP, and dGTP pools. In the 
deoxyadenosine-treated sample, the dGTP pool is below the detection limit (indicated by a dashed line). 
(B) Accumulation of dATP in T. brucei cultivated in the presence of various concentrations of 
deoxyadenosine. The results are plotted as a percentage of the total nucleotide pool (○, left axis) and as 
nmol/108 cells (■, right y-axis).  (C) Accumulation of dATP in deoxyadenosine-treated T. brucei (○), 
Madin Darby Bovine Kidney cells (MDBK) (♦), Balb/3T3 fibroblasts (▼), and human promyelocytic 
leukemia cells (HL-60) (▲). The cell culture media contained 2 µM deoxycoformycin to protect the 
deoxyadenosine from deamination in all experiments. The error bars in A and B show the standard errors 
from three independent experiments with p values indicated as: ** p <0.01, *** p <0.001, **** p 
<0.0001. 
Fig. 2. Cleavage of deoxyadenosine and adenosine by T. brucei cell extracts. (A) Cleavage of 
deoxyadenosine in the absence (■) or presence (●) of 5 mM potassium phosphate pH 7.4. HEPES-KOH 
(50 mM) was used as an additional buffering agent in all samples. (B) Similar experiments as in A but 
with adenosine as the substrate. The same symbols were used as in A to indicate the absence and presence 
of phosphate. Three independent experiments were performed with standard errors indicated.  
Fig. 3. TbMTAP knockdown experiments. (A) Western blot analysis of a 2-fold dilution series of 
recombinant TbMTAP protein and cell extracts from wild-type and knockdown T. brucei bloodstream 
forms. The cell extracts were prepared from the TC221 strain (wt), the NYSM parent strain (N), non-
induced TbMTAP knockdown cells (NI), and tetracycline-induced knockdown cells (I).  The membrane 
was blotted with -TbMTAP and -BiP antibodies (loading control for cell extracts). (B) 
Deoxyadenosine inhibition of proliferation in tetracycline-induced TbMTAP knockdown T. brucei (▲), 
non-induced cells (■), and the NYSM strain (▼). The graph shows the average results with standard 
errors from six independent experiments, and the table shows the calculated IC50 values in µM (**** 
indicates p < 0.0001). The cell culture media in B contained 2 µM deoxycoformycin. 
Fig. 4. Purification and characterization of recombinant TbMTAP. (A) SDS-PAGE analysis of purified 
TbMTAP with a molecular mass marker to the left (PagerulerTM Prestained Protein ladder, Fermentas Life 
Science). (B) Influence of pH on TbMTAP-mediated cleavage of 100 µM adenosine. The solution was 
buffered by a mixture of 25 mM acetic acid, 50 mM KH2PO4, and 10 mM Tris base that was pH-adjusted 
with KOH. (C) Adenosine cleavage (100 µM) activity under standard conditions (S) or in the presence of 
Tris-HCl, HEPES-KOH (H), MgCl2 (M), NaCl, KCl, sodium acetate (N), potassium acetate (K), or DTT 
with concentrations in mM indicated on top of the bars. (D) TbMTAP-mediated cleavage of 100 µM 
adenosine (▲) and the reverse reaction where adenosine is synthesized from 100 µM adenine and 100 
µM ribose-1-phosphate (□). (E) Lineweaver-Burk plot showing TbMTAP-mediated cleavage of various 
concentrations of 2-fluoro-2´-deoxyadenosine in the absence (▼) or presence of 0.75 µM (□) or 1.5 µM 
(▲) adenine. The results represent three independent experiments with standard errors shown. 
Fig. 5. Metabolism of deoxyadenosine (left), MTA (bottom left) and TbMTAP-resistant deoxyadenosine 
analogues (right). MTA is a byproduct when decarboxylated S-adenosylmethionine (dcSAM) is used in 
polyamine biosynthesis. The recycling of methionine back into dcSAM is not included in the figure.      
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Table 1. Accumulation of radiolabeled ATP and dATP in T. brucei TC221 bloodstream forms cultivated 
in the presence of different concentrations of 3H-deoxyadenosine combined with 2 μM deoxycoformycin. 
The results are based on three independent experiments with standard errors indicated for dATP (the 
remaining percentage is in ATP). 
 
[3H-dAdo] 
(mM) 
[3H-dATP] 
(% of total) 
[3H-ATP]  
(% of total) 
0.01 2.6 ± 0.1 97.4 
0.1 8.8 ± 0.5 91.2 
0.5 38 ± 3 62 
1.0 86 ± 4 14 
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Table 2. TbMTAP substrate selectivity. Kinetic parameters shown are Km, kcat (per polypeptide), and 
catalytic efficiency (kcat/Km) calculated by fitting Michaelis-Menten diagrams to hyperbolas using the 
GraphPad Prism software with standard errors of the regression analysis indicated.  
Substrate Km (μM) kcat (s−1) kcat/Km (s−1 × μM−1) 
MTA 0.09 ± 0.01 2.13 ± 0.06 24 
Ado 13 ± 1 8.4 ± 0.2 0.65 
dAdo 8.3 ± 0.7 9.6 ± 0.3 1.16 
2F-dAdo 5.0 ± 0.7 5.4 ± 0.2 1.08 
2Cl-dAdo 32 ± 6 6.4 ±0.4  0.20 
Cordycepin 260 ± 30 2.5 ± 0.1 0.0096 
Ara-A* 1210 ± 80 0.019 ± 0.001 0.000016 
Tubercidin  <0.003**  
Guo 150 ± 30 0.031 ± 0.002 0.00021 
dGuo 150 ± 10  0.058 ± 0.002 0.00039 
Ino 140 ± 20 0.079 ± 0.004 0.00056 
dIno 180 ± 30 0.128 ± 0.006 0.00071 
Urd 61 ± 10 0.052 ± 0.002 0.00086 
dUrd 77 ±12 0.036 ± 0.002 0.00047 
Cyd, dCyd, Thd  <0.003**   
Pi (with Ado)*** 690 ± 30 9.0 ± 0.2   
 * Not tested up to the kcat plateau due to the solubility limit of Ara-A (~1.8 mM) 
 **Measured with 100 µM substrate 
***Experiment performed under Pi limiting conditions (100 µM Ado) 
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Table 3. Growth inhibition of T. brucei bloodstream forms (TC221) and procyclic cells (S427) by 
deoxyadenosine, Ara-A, or cordycepin in the presence of 0, 10, or 100 µM adenine. The growth medium 
also contained 2 µM deoxycoformycin. The results show the average of 3 or 4 independent experiments 
with standard errors and p-values as compared to indicated controls: ns – not significant, * p <0.1, ** p 
<0.01, **** p <0.0001.  
 
Cell type Condition IC50 (µM) 
TC221 Only dAdo 205 ± 9 (ctrl) 
 + 10 µM Ade 109 ± 4 **** 
 + 100 µM Ade 52 ± 3 **** 
TC221 Only Ara-A 0.28 ± 0.04 (ctrl)  
 + 100 µM Ade 0.26 ± 0.01ns  
TC221 Only Cordycepin 0.0012 ± 0.0002  
 + 100 µM Ade 0.0022 ± 0.0002 * 
S427 Only dAdo 70 ± 10 (ctrl) 
S427 (APRT−/−) Only dAdo 33 ± 3 **  
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